29.10.2004

Official Journal of the European Union

C 266/1

Euro exchange rates (1)

28 October 2004

(2004/C 266/01)

1 euro =

	Currency	Exchange rate
USD	US dollar	1,2711
JPY	Japanese yen	135,20
DKK	Danish krone	7,4342
GBP	Pound sterling	0,6957
SEK	Swedish krona	9,0426
CHF	Swiss franc	1,5316
ISK	Iceland króna	88,12
NOK	Norwegian krone	8,1935
BGN	Bulgarian lev	1,9558
CYP	Cyprus pound	0,5763
CZK	Czech koruna	31,617
EEK	Estonian kroon	15,6466
HUF	Hungarian forint	246,38
LTL	Lithuanian litas	3,4528
LVL	Latvian lats	0,6743
MTL	Maltese lira	0,4308
PLN	Polish zloty	4,3424
ROL	Romanian leu	40 925
SIT	Slovenian tolar	239,89
SKK	Slovak koruna	39,955
TRL	Turkish lira	1 874 700
AUD	Australian dollar	1,7127
CAD	Canadian dollar	1,5606
HKD	Hong Kong dollar	9,892
NZD	New Zealand dollar	1,8645
SGD	Singapore dollar	2,1151
KRW	South Korean won	1 433,17
ZAR	South African rand	7,8529

(1)

Source: reference exchange rate published by the ECB.

29.10.2004

Official Journal of the European Union

C 266/2

Prior notification of a concentration

(Case COMP/M.3606 — SIEMENS/BONUS ENERGY)

Candidate case for simplified procedure

(2004/C 266/02)

(Text with EEA relevance)

On 22 October 2004, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Siemens Aktiengesellschaft (‘Siemens’, Germany) acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the whole of the undertaking BONUS Energy A/S (‘Bonus’, Denmark), controlled by Danregn Vindkraft A/S (Denmark) by way of purchase of shares.

The business activities of the undertakings concerned are:

—	for Siemens: global technology company active in the business areas Information Communication, Automation Control, Power, Transportation, Medical, Lighting, as well as Financing and Real Estate,

—	for Bonus: manufacturer of wind turbines.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (No +32/2/2964301 or 2967244) or by post, under reference number COMP/M.3606 — Siemens/Bonus Energy, to the following address:

European Commission

Directorate-General for Competition,

Merger Registry

J-70

B-1049 Bruxelles/Brussel

(1) OJ L 24, 29.1.2004, p. 1.

(2) Available on DG COMP website:

http://europa.eu.int/comm/competition/mergers/legislation/consultation/simplified_tru.pdf.

29.10.2004

Official Journal of the European Union

C 266/3

COMMUNICATION FROM THE COMMISSION

Corresponding values of the thresholds of Directives 2994/17/EC and 2004/18/EC of the European Parliament and of the Council as amended by Commission Regulation (EC) No 1874/2004

(2004/C 266/03)

(Text with EEA relevance)

The corresponding values in the national currencies other than euros of the thresholds of Directives 2004/17/EC and 2004/18/EC, as amended by Commission Regulation (EC) No 1874/2004 (1), are the following:

EUR 154 000	Danish krone (DKK)	1 144 511
	Swedish krona (SEK)	1 420 945
	Pound sterling (GBP)	99 685
	Czech koruna (CZK)	4 854 615
	Estonian kroon (EEK)	2 409 576
	Cyprus pound (CYP)	89 019
	Latvian lats (LVL)	91 791
	Lithuanian litas (LTL)	535 883
	Hungarian forint (HUF)	38 074 374
	Maltese lira (MTL)	63 665
	New Polish zloty (PLN)	613 300
	Slovenian tolar (SIT)	34 998 411
	Slovak koruna (SKK)	6 535 456
EUR 236 000	Danish krone (DKK)	1 753 926
	Swedish krona (SEK)	2 177 551
	Pound sterling (GBP)	152 765
	Czech koruna (CZK)	7 439 540
	Estonian kroon (EEK)	3 692 598
	Cyprus pound (CYP)	136 419
	Latvian lats (LVL)	140 666
	Lithuanian litas (LTL)	821 223
	Hungarian forint (HUF)	58 347 742
	Maltese lira (MTL)	97 564
	New Polish zloty (PLN)	939 862
	Slovenian tolar (SIT)	53 633 929
	Slovak koruna (SKK)	10 015 375
EUR 5 923 000	Danish krone (DKK)	44 019 088
	Swedish krona (SEK)	54 651 002
	Pound sterling (GBP)	3 834 007
	Czech koruna (CZK)	186 713 544
	Estonian kroon (EEK)	92 674 812
	Cyprus pound (CYP)	3 423 759
	Latvian lats (LVL)	3 530 360
	Lithuanian litas (LTL)	20 610 618
	Hungarian forint (HUF)	1 464 379 973
	Maltese lira (MTL)	2 448 614
	New Polish zloty (PLN)	23 588 140
	Slovenian tolar (SIT)	1 346 075 268
	Slovak koruna (SKK)	251 360 438
EUR 473 000	Danish krone (DKK)	3 515 284
	Swedish krona (SEK)	4 364 330
	Pound sterling (GBP)	306 177
	Czech koruna (CZK)	14 910 604
	Estonian kroon (EEK)	7 400 842
	Cyprus pound (CYP)	273 415
	Latvian lats (LVL)	281 928
	Lithuanian litas (LTL)	1 645 926
	Hungarian forint (HUF)	116 942 719
	Maltese lira (MTL)	195 542
	New Polish zloty (PLN)	1 883 706
	Slovenian tolar (SIT)	107 495 121
	Slovak koruna (SKK)	20 073 187

(1) OJ L 326, 29.10.2004, p. 17.

29.10.2004

Official Journal of the European Union

C 266/5

Summary of Community decisions on marketing authorizations in respect of medicinal products from 15 September 2004 to 15 October 2004

(Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93 (1))

(2004/C 266/04)

Issuing of a marketing authorisation (Article 12 of Council Regulation (EEC) No 2309/93): Accepted

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community Register	Date of notification
20.9.2004	Angiox	The Medicines Company UK Ltd, Suite B, Park House, 11 Milton Park, Abingdon, Oxfordshire OX14 4RS, United Kingdom	EU/1/04/289/001	22.9.2004
20.9.2004	Alimta	Eli Lilly Nederland BV, Grootslag 1-5, 3991 RA Houten, Nederland	EU/1/04/290/001	22.9.2004
20.9.2004	Raptiva	Serono Europe Limited, 56, Marsh Wall, London E14 9TP, United Kingdom	EU/1/04/291/001-002	22.9.2004
21. 9.2004	Protelos	Les Laboratoires Servier, 22, rue Garnier, F-92200 Neuilly-sur-Seine	EU/1/04/288/001-006	23.9.2004
21. 9.2004	Osseor	Les Laboratoires Servier, 22, rue Garnier, F-92200 Neuilly-sur-Seine	EU/1/04/287/001-006	23.9.2004
27. 9.2004	Apidra	Aventis Pharma Deutschland GmbH, Brueningstrasse 50, D-65926 Frankfurt am Main,	EU/1/04/285/001-020	29. 9.2004
13.10.2004	Wilzin	Orphan Europe SARL, Immeuble ‘Le Guillaumet’ F-92046 Paris-La-Défense	EU/1/04/286/001-002	18.10.2004

Modification of a marketing authorisation (Article 12 of Council Regulation (EEC) No 2309/93) Accepted

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community Register	Date of notification
20.9.2004	Remicade	Centocor BV, Einsteinweg 101, 2333 CB Leiden, Nederland	EU/1/99/116/001-003	22.9.2004
20.9.2004	Azomyr	Schering Plough Europe, Rue de Stalle, 73, B-1180 Brussels	EU/1/00/157/014-021	22.9.2004
20.9.2004	Aerius	Schering Plough Europe, Rue de Stalle, 73, B-1180 Brussels	EU/1/00/160/014-021	22.9.2004
20.9.2004	Neoclarityn	Schering Plough Europe, Rue de Stalle, 73, B-1180 Brussels,	EU/1/00/161/014-021	22.9.2004
20.9.2004	Lantus	Aventis Pharma Deutschland GmbH, D-65926 Frankfurt am Main,	EU/1/00/134/008-011 EU/1/00/134/018-021	22.9.2004
20.9.2004	Velcade	Millennium Pharmaceuticals, Ltd, Building 3, Chiswick Park, 566 Chiswick High Road, Chiswick, London, W4 5YA United Kingdom	EU/1/04/274/001	22.9.2004
20.9.2004	Velcade	Janssen-Cilag International NV, Turnhoutsewe 30, B–2340 Beerse	EU/1/04/274/001	23.9.2004
20.9.2004	Ovitrelle	Serono Europe Limited, 56, Marsh Wall, London E14 9TP, United Kingdom	EU/1/00/165/001-007	22.9.2004
21.9.2004	Carbaglu	Orphan Europe, Immeuble ‘Le Guillaumet’, F-92046 Paris-La-Défense	EU/1/02/246/001-002	23.9.2004
21.9.2004	KOGENATE Bayer	Bayer AG, D-51368 Leverkusen, Deutschland	EU/1/00/143/004-006	23.9.2004
23.9.2004	Remicade	Centocor B.V., Einsteinweg 101, 2333 CB Leiden, Nederland	EU/1/99/116/001-003	27.9.2004
24.9.2004	Insuman	Aventis Pharma Deutschland GmbH, Brueningstrasse 50, D-65926 Frankfurt am Main,	EU/1/97/030/065-084	29.9.2004
24.9.2004	InductOs	Wyeth Europa Ltd., Huntercombe Lane South, Taplow, Maidenhead, Berkshire, SL6 0PH, United Kingdom	EU/1/02/226/001	28.9.2004
24.9.2004	Enbrel	Wyeth Europa Limited, Huntercombe Lane South, Taplow, Maidenhead, Berkshire, SL6 0PH, United Kingdom	EU/1/99/126/001-003	28.9.2004
27.9.2004	SonoVue	Bracco International BV, Strawinskylaan 3051, 1077ZX Amsterdam, Nederland	EU/1/01/177/001-002	29.9.2004
27.9.2004	Ceprotin	Baxter AG, Industriesstrasse 67, 1220 Vienna, Österreich	EU/1/01/190/001-002	29.9.2004
27.9.2004	Avonex	Biogen Idec France, ‘Le Capitole’ 55, avenue des Champs Pierreux, F-92012 Nanterre Cedex	EU/1/97/033/001-003	30. 9.2004
13.10.2004	Revasc	Canyon Pharmaceuticals Ltd, 20-22 Bedford Row - WC1R 4JS London - United Kingdom	EU/1/97/043/001-002	19.10.2004
13.10.2004	Revasc	Aventis Pharma SA, 20 Avenue Raymond Aron, Antony Cedex F-92165	EU/1/97/043/001-002	18.10.2004
13.10.2004	Arava	Aventis Pharma Deutschland GmbH, D-65926 Frankfurt am Main	EU/1/99/118/001-010	18.10.2004
13.10.2004	Vaniqa	Shire Pharmaceutical Contracts Ltd, Hampshire International Business Park, Chineham, Basingstoke, Hampshire RG24 8EP, United Kingdom	EU/1/01/173/001-003	18.10.2004
13.10.2004	NovoRapid	Novo Nordisk A/S, Novo Allé, DK-2880 Bagsvaerd	EU/1/99/119/001-014	18.10.2004
13.10.2004	Levviax	Aventis Pharma SA, 20 Avenue Raymond Aron, F-92160 Antony	EU/1/01/192/001-005	19.10.2004
15.10.2004	Ketek	Aventis Pharma SA, 20 Avenue Raymond Aron, F-92160 Antony	EU/1/01/191/001-005	19.10.2004
15.10.2004	Viramune	Boehringer Ingelheim International GmbH, Binger Strasse, 173 D-55216 Ingelheim am Rhein, Deutschland	EU/1/97/055/001-002	19.10.2004
15.10.2004	Fuzeon	Roche Registration Limited, 40 Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AY	EU/1/03/252/001-003	20.10.2004
15.10.2004	NovoRapid	Novo Nordisk A/S, Novo Allé, DK-2880 Bagsvaerd	EU/1/99/119/001 EU/1/99/119/003 EU/1/99/119/005-014	19.10.2004

Withdrawal of a marketing authorisation (Article 12 of Council Regulation (EEC) No 2309/93)

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community Register	Date of notification
28.9.2004	Ixense	Takeda Europe R&D Centre Ltd, Savanah House, 11/12 Charles II Street, London SW1Y 4QU, United Kingdom	EU/1/01/181/001-007	30.9.2004

(1) OJ L 214, 24.8.1993, p. 1.

29.10.2004

Official Journal of the European Union

C 266/8

Prior notification of a concentration

(Case COMP/M.3596 — THYSSENKRUPP/HDW)

Candidate case for simplified procedure

(2004/C 266/05)

(Text with EEA relevance)

On 19 October 2004, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking ThyssenKrupp AG (‘ThyssenKrupp’, Germany) acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the whole of the undertaking Howaldtswerke-Deutsche Werft AG (‘HDW’), controlled by One Equity Partners LLC (‘OEP’, USA), itself belonging to the J.P. Morgan Chase Corporation, by way of purchase of shares. By invoking Article 296(1)b of the EC Treaty, the German ministry for economic affairs has ordered ThyssenKrupp not to notify the military part of this transaction to the European Commission.

The business activities of the undertakings concerned are:

—	for ThyssenKrupp: active in numerous industries including steel, mechanical engineering, plant construction, elevators, plastic products and car parts. Its Blohm& Voss and Nordseewerke Emden shipyards are active in design, supply and repair of civil and military vessels,

—	for HDW: civil shipbuilding (passenger- and container ships, yachts), military shipbuilding (submarines and naval surface vessels) and ship repair services through shipyards in Germany, Sweden (Kockums ) and Greece (Hellenic Shipyard),

—	for OEP: financial investments in various industries.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (No +32/2/2964301 or 2967244) or by post, under reference number Case COMP/M.3596 — ThyssenKrupp/HDW, to the following address:

European Commission

Directorate-General for Competition,

Merger Registry

J-70

B-1049 Bruxelles/Brussel

(1) OJ L 24, 29.1.2004, p. 1.

(2) Available on DG COMP website:

http://europa.eu.int/comm/competition/mergers/legislation/consultation/simplified_tru.pdf.

29.10.2004

Official Journal of the European Union

C 266/10

Prior notification of a concentration

(Case COMP/M.3604 — PERMIRA/AHOLD IBERIA)

Candidate case for simplified procedure

(2004/C 266/07)

(Text with EEA relevance)

On 22 October 2004, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking CMA, S.à.r.l. (Luxembourg) ultimately controlled by Permira Holdings Ltd (‘PHL’, Guernsey), acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the whole of the undertaking Ahold Iberia B.V. (‘Ahold Iberia’, The Netherlands) by way of purchase of shares.

The business activities of the undertakings concerned are:

—	for undertaking PHL: private equity fund,

—	for undertaking Ahold Iberia: through Ahold Supermercados, active in the procurement, wholesale and retail of daily consumer goods and related services in Spain.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (No +32 2 2964301 or 2967244) or by post, under reference number COMP/M.3604 — Permira/Ahold Iberia, to the following address:

European Commission

Directorate-General for Competition,

Merger Registry

J-70

B-1049 Bruxelles/Brussel

(1) OJ L 24, 29.1.2004, p. 1.

(2) Available on DG COMP website:

http://europa.eu.int/comm/competition/mergers/legislation/consultation/simplified_tru.pdf.

		ISSN 1725-2423
Official Journal of the European Union		C 266

English edition	Information and Notices	Volume 47 29 October 2004

Notice No	Contents	page
	I Information
	Commission
2004/C 266/1	Euro exchange rates	1
2004/C 266/2	Prior notification of a concentration (Case COMP/M.3606 — SIEMENS/BONUS ENERGY) — Candidate case for simplified procedure ( 1 )	2
2004/C 266/3	Communication from the Commission — Corresponding values of the thresholds of Directives 2994/17/EC and 2004/18/EC of the European Parliament and of the Council as amended by Commission Regulation (EC) No .../2004 ( 1 )	3
2004/C 266/4	Summary of Community decisions on marketing authorizations in respect of medicinal products from 15 September 2004 to 15 October 2004(Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93)	5
2004/C 266/5	Prior notification of a concentration (Case COMP/M.3596 — THYSSENKRUPP/HDW) — Candidate case for simplified procedure ( 1 )	8
2004/C 266/6	Prior notification of a concentration (Case COMP/M.3579 — WPP/GREY) ( 1 )	9
2004/C 266/7	Prior notification of a concentration (Case COMP/M.3604 — PERMIRA/AHOLD IBERIA) — Candidate case for simplified procedure ( 1 )	10

	III Notices
	Commission
2004/C 266/8	AGIS work programme 2005	11